Efficacy of second‑line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non‑small cell lung cancer without epidermal growth factor receptor mutations

  • Authors:
    • Sung Yong Lee
    • Eun Joo Kang
    • Suk Young Lee
    • Hong Jun Kim
    • Kyung Hoon Min
    • Gyu Young Hur
    • Jae Jeong Shim
    • Kyung Ho Kang
    • Sang Cheul Oh
    • Jae Hong Seo
    • Jun Suk Kim
  • View Affiliations

  • Published online on: November 3, 2017     https://doi.org/10.3892/ol.2017.7350
  • Pages:600-609
Metrics: HTML 0 views | PDF 0 views
0

Abstract

The present study investigated the importance of comorbidity scores and clinical parameters in elderly patients with non‑small cell lung cancer (NSCLC) not harboring epidermal growth factor receptor (EGFR) mutations who received second‑line chemotherapy. The present study also compared the efficacy of tyrosine kinase inhibitor and cytotoxic chemotherapy as second‑line treatment in elderly patients. The present study retrospectively reviewed the treatment of elderly patients with NSCLC (≥70 years old) who received second‑line chemotherapy at Korea University Guro Hospital. Patients who had an EGFR mutation were excluded from the analysis. Between 2005 and 2013, 126 patients were included in the present study. The median progression‑free survival (PFS) and overall survival (OS) for all patients who received second‑line treatment were 2.47 months [95% confidence interval (CI), 2.08‑2.86] and 8.63 months (95% CI, 5.99‑11.28), respectively. A total of 52 patients (41.3%) were treated with tyrosine kinase inhibitor (TKI) and 74 (58.7%) were treated with chemotherapy. No difference was observed in the median PFS and OS between the TKI and chemotherapy groups (P=0.287 for PFS and P=0.374 for OS). The Charlson comorbidity index was not associated with survival, whereas a simplified comorbidity score and clinical factors, including poor performance status, short PFS of first‑line chemotherapy, presence of brain metastasis and low serum albumin and sodium levels were significant prognostic factors in these elderly patients. Second‑line chemotherapy was not beneficial to patients who had at least 3 of these factors and a median OS of 1.73 months, whereas patients who had less than 2 of these factors had a median OS of 11.50 months. For elderly lung cancer patients without EGFR mutations, clinical parameters were the most important factors affecting survival, rather than the types of drugs.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Lee, S.Y., Kang, E.J., Lee, S.Y., Kim, H.J., Min, K.H., Hur, G.Y. ... Kim, J.S. (2018). Efficacy of second‑line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non‑small cell lung cancer without epidermal growth factor receptor mutations. Oncology Letters, 15, 600-609. https://doi.org/10.3892/ol.2017.7350
MLA
Lee, S. Y., Kang, E. J., Lee, S. Y., Kim, H. J., Min, K. H., Hur, G. Y., Shim, J. J., Kang, K. H., Oh, S. C., Seo, J. H., Kim, J. S."Efficacy of second‑line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non‑small cell lung cancer without epidermal growth factor receptor mutations". Oncology Letters 15.1 (2018): 600-609.
Chicago
Lee, S. Y., Kang, E. J., Lee, S. Y., Kim, H. J., Min, K. H., Hur, G. Y., Shim, J. J., Kang, K. H., Oh, S. C., Seo, J. H., Kim, J. S."Efficacy of second‑line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non‑small cell lung cancer without epidermal growth factor receptor mutations". Oncology Letters 15, no. 1 (2018): 600-609. https://doi.org/10.3892/ol.2017.7350